QMS Medical Allied Services reported a 13% decline in consolidated net profit to ₹119.17 crore for the year ended March 31, 2026, despite an 11% rise in revenue from operations to ₹172.9 crore. Rising expenses impacted the bottom line, with total expenses increasing to ₹157.49 crore from ₹139.07 crore in the previous year. Profit before tax stood at ₹164.40 crore compared to ₹186.62 crore in FY25. The company released its investor presentation for Q4 and FY26 on June 04, 2026, detailing its operational highlights and strategic initiatives.

The board, in its meeting held on May 30, 2026, recommended a final dividend of ₹0.50 per equity share, or 5%, subject to shareholder approval. H.H. Dedhia And Associates, the statutory auditors, issued an unmodified opinion on the financial statements. The board also approved the re-appointment of M/s. Khushbu Parekh & Co., Chartered Accountants, as internal auditors for FY 2026-27 and the Information Memorandum for migration from the NSE Emerge platform to the main board.

Consolidated Financial Performance

Profit attributable to owners of the company declined to ₹101.32 crore from ₹120.92 crore, while non-controlling interest accounted for ₹17.85 crore. Basic and diluted earnings per share (EPS) fell to ₹5.40 from ₹6.65. The consolidated results include subsidiary Saarthi Healthcare Private Limited, which reported total assets of ₹43.28 crore as of March 31, 2026.

Standalone Financial Performance

On a standalone basis, net profit fell to ₹66.91 crore from ₹104.21 crore in FY25. Revenue from operations grew to ₹152.30 crore from ₹144.87 crore, while total expenses rose to ₹143.20 crore from ₹130.90 crore. Profit before tax was ₹94.52 crore, down from ₹144.22 crore in the prior year.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0FMW01018/b68f1e4202d24b21.pdf

QMS Medical Allied Services Limited has confirmed compliance with the Structured Digital Database (SDD) requirements for the financial year ended March 31, 2026. The company submitted the necessary compliance certificate to the National Stock Exchange of India Ltd., certifying that its internal systems for tracking Unpublished Price Sensitive Information (UPSI) are fully operational and secure. This adherence to regulatory standards mitigates the risk of insider trading and ensures transparency in information dissemination.

Regulatory Filing Details

The submission was made pursuant to Regulation 3(5) and 3(6) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. As the provisions of Regulation 24A of SEBI (LODR) Regulations, 2015 are not applicable to the entity, QMS Medical Allied Services was required to file the certificate within 60 days from the end of the financial year. The document was certified by M/s. Maharshi Ganatra & Associates, a Practicing Company Secretary.

Compliance Status

The certificate validates that the company maintains a non-tamperable digital database with controlled access and a comprehensive audit trail. It confirms that all UPSI disseminated during the previous quarter was captured with the necessary details, including the nature of the information and the precise date and time. The system is designed to retain records for a period of 8 years.

Key Certification Points

The certification further clarifies that the company was required to capture one event during the quarter and successfully recorded the said event. No instances of non-compliance were observed in the quarter ended March 31, 2026.